Category: Pharma
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access The European Union’s Health Technology Assessment framework is transforming how pharmaceutical companies prepare clinical evidence, demonstrate therapeutic value and plan market access across Europe. As Joint Clinical Assessment (JCA) implementation progresses, manufacturers face growing pressure to align clinical development, Real-World…
EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?
EU-HTA’s 2026 Scientific Consultation Window: Can Pharma Fix Tomorrow’s PICO Problems Before Phase III? Europe’s pharmaceutical evidence landscape is changing. Under the EU Health Technology Assessment (HTA) Regulation, generating strong clinical evidence is no longer sufficient on its own. Pharmaceutical companies must also consider whether their clinical development programmes will address the comparative evidence needs…
Who Gets to Define the PICO? Patient and Clinician Input in EU JCA Evidence Planning
Who Gets to Define the PICO? Why Patient and Clinician Input Matters for EU JCA Evidence Planning A treatment may perform well in a clinical trial. But does the evidence answer the questions that matter to patients, clinicians and HTA assessors across Europe? That question is becoming harder to leave until submission. On 14 September…
JCA to National Reimbursement: A Technical Evidence Framework
From JCA Relative Effects to National Reimbursement: Managing PICO Multiplicity, Indirect Comparisons and Residual Evidence Gaps The central technical challenge of the EU Health Technology Assessment Regulation is not simply producing a Joint Clinical Assessment (JCA) dossier on time. It is preserving the validity and decision relevance of one evidence package as it moves through…
EU JCA Evidence Requirements: Lessons for Pharma in 2026
EU JCA Is Now Operational: What the First Assessments Reveal About Evidence, RWE and Market Access The European Union’s Joint Clinical Assessment framework has moved decisively from policy into practice. Since the EU Health Technology Assessment Regulation became applicable in January 2025, pharmaceutical and biotechnology companies have been preparing for new timelines, evidence requirements and…
EU Pharma Package 2026: What Market Access Teams Should Prepare for Before Formal Adoption
EU Pharma Package 2026: What Market Access Teams Should Prepare for Before Formal Adoption Europe is approaching the most significant reform of its pharmaceutical legislation in more than two decades. Following the political agreement reached by the European Parliament and the Council in December 2025, the compromise texts for the revised EU pharmaceutical framework were…
EMA and EU-HTA Alignment: One Evidence Strategy for Regulatory Approval and JCA
EMA and EU-HTA Alignment Building One Evidence Strategy for Regulatory Approval and Joint Clinical Assessment Europe’s evidence environment has entered a new phase. A medicine can now move through the European Medicines Agency’s regulatory assessment while, in parallel, entering the EU-level Joint Clinical Assessment process. These procedures remain legally and methodologically distinct, but manufacturers must…
JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams
JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams The European Union Health Technology Assessment Regulation has created a common framework for assessing the relative clinical effectiveness and safety of eligible health technologies. However, the introduction of Joint Clinical Assessment does not establish a single European pricing, reimbursement or market-access…
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.…
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
